Lexicon Pharmaceuticals, Inc. Stock Nasdaq
Equities
US5288721047
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 25.81M | Sales 2025 * | 77.52M | Capitalization | 379M |
---|---|---|---|---|---|
Net income 2024 * | -199M | Net income 2025 * | -193M | EV / Sales 2024 * | 14.7 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.89 x |
P/E ratio 2024 * |
-2.17
x | P/E ratio 2025 * |
-2.43
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.99% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
Director/Board Member | 65 | 07-08-27 |
1st Jan change | Capi. | |
---|---|---|
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |